Revolutionizing Liver Toxicity Testing with 3D Microtissues
InSphero and FDA's NCTR Conduct Groundbreaking Study
InSphero, a distinguished leader in 3D cell culture technology, has made significant strides in drug safety testing. Collaborating with the FDA's National Center for Toxicological Research (NCTR), they have published an extensive benchmarking study on liver toxicity using their revolutionary 3D InSight™ Human Liver Microtissues. This large-scale study assessed the hepatotoxicity of 152 FDA-approved drugs, offering promising insights into early-stage drug safety testing.
Understanding the Importance of Early Detection
Through this study, it was found that approximately 80% of the drugs that were ultimately withdrawn due to liver safety issues were correctly flagged by the innovative 3D liver microtissue platform. This remarkable success underscores the potential of this high-throughput safety technology in identifying dangerous compounds early in the development phase, leading to lower attrition rates in drug development.
A Breakthrough in Predicting Drug-Induced Liver Injury
The study's findings were published in a peer-reviewed journal, showcasing a significant leap forward in predicting drug-induced liver injury (DILI), which often leads to halted projects and substantial financial losses in the pharmaceutical sector. InSphero's unique 3D InSight™ microtissue models effectively combine hepatocytes and other essential liver cell types, producing enhanced biological accuracy. Consequently, while 80% of withdrawn drugs were flagged as toxic, an impressive 89% of the safe compounds were also correctly identified.
Industry Transformation with Human-Based Testing
In light of the FDA Modernization Act 2.0, the study reinforces the necessity for human-centric testing solutions like InSphero’s 3D platform. This shift from animal-based testing not only streamlines drug development but also directs resources to safer and more reliable drug candidates. InSphero's technology aligns with the industry's changing landscape, providing pivotal early drug safety data.
Creating Economic Value Through Predictivity
Utilizing InSphero's microtissue models is predicted to deliver notable economic benefits to drug developers. By identifying hepatotoxic compounds sooner, companies can significantly cut down on preclinical costs, which are often exorbitant. Additionally, this study reinforces the reproducibility of InSphero's liver model, promising reliable outcomes as the research scales up.
A Model for the Future of Drug Safety
Dr. Madhu Nag, Chief Scientific Officer of InSphero, emphasized that their 3D InSight™ Liver Safety Platform melds biological precision with the efficiency and readiness required for industrial applications. This integrated approach supports drug developers in making better-informed decisions earlier during the drug development life cycle. By reducing late-stage failures, InSphero accelerates the timeline for bringing safe drugs to market.
Continuous Learning and Innovation
As industry dynamics evolve, InSphero remains committed to utilizing advanced methods that redefine drug discovery and safety testing. Their innovative technologies enhance the speed at which effective therapies reach patients, illustrating their dedication to research and development.
The future of drug safety testing is promising with breakthroughs like InSphero's 3D microtissues paving the way for a safer and more effective pharmaceutical landscape.
Frequently Asked Questions
What is the significance of the InSphero and FDA's NCTR study?
The study demonstrates the effectiveness of 3D liver microtissues in accurately predicting liver toxicity, paving the way for safer drug development.
How does the 3D InSight™ technology work?
This innovative technology combines hepatocytes from multiple individuals with various liver cells, accurately mimicking liver physiology for enhanced predictability.
What are the economic benefits of using this technology?
By highlighting toxic compounds earlier, drug developers can save on costly preclinical trials and improve overall R&D productivity.
How does this study impact animal testing?
The findings support a shift towards human-based in vitro testing, reducing reliance on animal models and ensuring more relevant results.
Who can benefit from InSphero’s 3D liver safety testing?
Drug developers and pharmaceutical companies looking to enhance the safety of their therapeutics during early development stages can greatly benefit from this innovative platform.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Marinus Pharmaceuticals Achieves Milestone with New Patent
- VSE Corporation Expands Footprint with Kellstrom Aerospace Acquisition
- OFS Credit Company Delivers September 2024 NAV Insights
- Gurbir S. Grewal Enhances Milbank With Vast Expertise
- United Airlines Beats Expectations with Strong Q3 2024 Results
- STAND 8 Marks Major Milestone with Significant Acquisition
- United Airlines Surprises with Strong Q3 Earnings and Growth
- PAYO Stock Reaches New Heights with Strong Market Confidence
- Johnson & Johnson Exceeds Expectations with Cancer Drug Sales
- Revolutionizing Property Design: The Rise of Restyle Tool
Recent Articles
- Trump's World Liberty Financial Token Sale Raises $220 Million
- E Source Celebrates Utility Leaders at Forum 2024 Awards
- CIRO Schedules Hearing for Alleged Misconduct by Advisor
- How AI Is Revitalizing the Cloud Computing Sector
- BioNJ and Medidata Join Forces for Clinical Equity in Trials
- China's NEVs Rebound in Q3, Easing EV Market Concerns
- Dominion Energy's Strategic Plan for Sustainable Power Growth
- Exelixis Achieves Court Victory in Patent Dispute with MSN
- New Affordable Housing Units Launched in Mirabel Area
- Exciting Culinary Experiences Await at 2025 Food Festival
- Understanding September's Housing Market Trends and Insights
- Osaic Names Kristy Britt New Chief Financial Officer
- UCB Innovates with Myasthenia Gravis Scholarship for Education
- Empowering Citizens Through Town Halls on Borders and Elections
- HealthMetrix Reveals Top Medicare Advantage Plans for 2025
- Burke & Herbert Bank Foundation Strengthens Community Ties
- Transforming Lives: AI Innovation at Tech World '24 Event
- Syngenta and Taranis Collaborate for AI-Enhanced Agronomy
- AT&T Experiences Remarkable Stock Surge to 52-Week Peak
- Crestron Launches Flagship Center, Redefining Workspaces and Homes
- XPeng Faces Downgrade Amidst Market Challenges and Growth
- GSK's Phase III Breakthrough with Depemokimab for CRSwNP
- Sound Point Meridian Capital Reports Positive NAV Per Share Estimate
- Willdan Group Achieves Milestone with 52-Week High Stock Surge
- Phoenix Motor's Journey: Compliance Path and Growth Prospects
- Notable Labs Faces Bankruptcy and Leadership Changes
- STMicroelectronics N.V. Investors Urged to Act Before Deadline
- Current Trends Affecting Advanced Micro Devices Stock Performance
- Seelos Therapeutics Moves to OTC Market After Nasdaq Delisting
- Star Fashion Culture Holdings Limited Concludes $8.6M IPO Successfully
- Falling Stock: Netflix Faces Headwinds from Growth Risks
- Celsius Holdings Stock Update: Challenges and Strategies Ahead
- Analysts Optimistic on McDonald's Stock Ahead of Q3 Earnings
- Understanding the Current Challenges for Applied Materials (AMAT)
- Enphase Energy Faces Downgrade Amid Competitive Pressures
- Exploring Recent Trends in Albemarle Options Trading
- Analyzing Recent Trends in Trump Media & Technology Options
- Market Insights: How Investors Are Navigating ILMN Options
- Westland Insurance Celebrates Recognition as Top Employer
- Exploring Investment Potential in Nu Holdings Amid Analyst Insights
- Eramet Adjusts 2024 Manganese and Nickel Production Goals
- MercadoLibre Soars: Capitalizing on Argentina's Economic Growth
- Unlocking the Growth Potential: Investing in Motorola Solutions
- Understanding Clear Secure's Rising Short Interest Dynamics
- Evaluating Ferguson Enterprises Stock Growth from Five Years Ago
- Understanding Biomarin Pharmaceutical's Current Market Sentiment
- Understanding Recent Trends in Old Dominion Freight Line's Short Interest
- BOK Financial's Strong Fee Income Strategy Fuels Analyst Upgrade
- Market Dynamics: Stocks, Earnings, and Sector Trends This Week
- Life Flight Network Expands Air Medical Services with New Aircraft